Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)Symptoms, Doctors, Treatments, Advances & More
Learn About Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Kerry Savage practices practicing medicine in Vancouver, Canada. Savage is rated as an Elite expert by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). They are also highly rated in 18 other conditions, according to our data. Their clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.
Bassett Medical Center
Anush Patel is a Hematologist practicing medicine in Cooperstown, New York. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). He is also highly rated in 57 other conditions, according to our data. His clinical expertise encompasses Angiosarcoma, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Iron Deficiency Anemia.
Sylvia Hartmann practices practicing medicine in Essen, Germany. Ms. Hartmann is rated as an Elite expert by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and B-Cell Lymphoma.
Summary: This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cel...
Objective: * To develop the data collection infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pediatric patients diagnosed with NLPHL. Secondary Objective: * To examine differences in baseline and longitudinal changes in PROs based on disease characteristics, disease status, and treatment strategies among adult and pediat...